- Home
- KROS vs ARVN Comparison
KROS vs ARVN Comparison
Compare KROS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- ARVN
- Stock Information
- Founded
- KROS 2015
- ARVN 2015
- Country
- KROS United States
- ARVN United States
- Employees
- KROS N/A
- ARVN N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- ARVN Health Care
- Exchange
- KROS Nasdaq
- ARVN Nasdaq
- Market Cap
- KROS 565.0M
- ARVN 456.2M
- IPO Year
- KROS 2020
- ARVN 2018
- Fundamental
- Price
- KROS $15.65
- ARVN $7.83
- Analyst Decision
- KROS Buy
- ARVN Buy
- Analyst Count
- KROS 14
- ARVN 22
- Target Price
- KROS $20.56
- ARVN $20.21
- AVG Volume (30 Days)
- KROS 445.6K
- ARVN 1.4M
- Earning Date
- KROS 11-05-2025
- ARVN 10-29-2025
- Dividend Yield
- KROS N/A
- ARVN N/A
- EPS Growth
- KROS N/A
- ARVN N/A
- EPS
- KROS 0.47
- ARVN N/A
- Revenue
- KROS $232,844,000.00
- ARVN $372,800,000.00
- Revenue This Year
- KROS $5,579.44
- ARVN $4.87
- Revenue Next Year
- KROS N/A
- ARVN N/A
- P/E Ratio
- KROS $33.59
- ARVN N/A
- Revenue Growth
- KROS 85820.30
- ARVN 299.57
- 52 Week Low
- KROS $9.12
- ARVN $5.90
- 52 Week High
- KROS $72.37
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- KROS 59.98
- ARVN 55.97
- Support Level
- KROS $15.25
- ARVN $7.58
- Resistance Level
- KROS $16.00
- ARVN $8.23
- Average True Range (ATR)
- KROS 0.61
- ARVN 0.37
- MACD
- KROS 0.03
- ARVN 0.05
- Stochastic Oscillator
- KROS 78.77
- ARVN 68.50
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.